Skip to content

Isradipine

    DEA Class; Rx

    Common Brand Names; DynaCirc

    •  Calcium Channel Blockers; 
    • Calcium Channel Blockers, Dihydropyridine
    Dihydropyridine calcium-channel blocker
    Used for hypertension and angina
    More potent than nifedipine and amlodipine; longer-acting than regular-release nifedipine but shorter-acting than amlodipine

    Indicated for the treatment of hypertension.

    For the treatment of chronic stable angina.
    For the treatment of hypertensive urgency.

    Hypersensitivity to isradipine or other calcium channel blockers; hypotension (<90 mm Hg systolic)

    • Headache (2-22%)
    • Edema (1-9%)
    • Dizziness (2-8%)
    • Palpitation (1-5%)
    • Flushing (1-5%)
    • Tachycardia (1-3%)
    • Chest pain (2-3%)
    • Rash (2%)
    • Nausea (1-5%)
    • Vomiting (≤1%)
    • Diarrhea (≤ 3%)
    • Weakness (≤1%)
    • Dyspnea (1-3%)
    • Urinary frequency (1-3%)
    • Drug-induced gingival hyperplasia
    • Angioedema
    • Drowsiness
    • Hyperhidrosis
    • Leg pain
    • Nasal congestion
    • Drug fever
    • Dysuria
    • Impotence
    • Pruritus
    • Urticaria
    • Weight gain
    • Myocardial infarction

    Use caution in CHF, aortic stenosis, hypotension (initially or after dose increases), persistent progressive dermatologic reactions, exacerbation of angina (during initiation of treatment, after dose increase, or withdrawal of beta blocker), liver impairment

    Reflex tachycardia resulting in angina and/or MI in patients with obstructive coronary disease reported

    Peripheral edema may occur within 2-3 weeks of initiating therapy

    Hypotension with or without syncope is possible (particularly with severe aortic stenosis)

    Avoid taking with grapefruit juice

    Pregnancy Category: C

    Lactation: not known if excreted into breast milk

    Adults

    20 mg/day PO.

    Geriatric

    20 mg/day PO.

    Adolescents

    Safety and efficacy have not been established; however, doses up to 0.6 to 0.8 mg/kg/day PO, not to exceed 10 to 20 mg/day PO, have been recommended.

    Children

    Safety and efficacy have not been established; however, doses up to 0.6 to 0.8 mg/kg/day PO, not to exceed 10 to 20 mg/day PO, have been recommended.

    Infants

    Safety and efficacy have not been established; however, a mean dose of 0.27 +/- 0.11 mg/kg/day PO has been reported.

    Neonates

    Safety and efficacy have not been established; however, a mean dose of 0.27 +/- 0.11 mg/kg/day PO has been reported.

    Isradipine

    capsule

    • 2.5mg
    • 5mg

    tablet, extended release

    • 5mg
    • 10mg